Crosslink Therapeutics Inc.
These Form D notices describe private placements reported to the SEC. Read Form D/A amendments alongside the original disclosures.
through Oct 20, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Differences between reported disclosures
Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.
| Field | May 15, 2025 · D | Oct 20, 2026 · D | Later minus earlier |
|---|---|---|---|
| Reported offering amount | $8,000,000 | $5,500,000 | $-2,500,000 |
| Reported amount sold | $4,250,000 | $5,500,000 | $1,250,000 |
| Reported investor count | — | 8 | — |
| Reported minimum investment | $0 | $0 | $0 |
Earlier SEC source: 0002067583-25-000002 · Later SEC source: 0002067583-26-000002
Choose filings to compare · Research this issuer step by step
Latest available filing snapshot: how to read these fields
- Reported offering amount
- $5,500,000
- Reported exemptions
- Rule 506(b)
- Reported amount sold
- $5,500,000
This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.
Filings by year
- 20251 filing
- 20261 filing
Submission counts, including amendments; not dollars raised or distinct funding rounds.
Related person name and locality match
Matches in stored disclosures are research leads. They do not establish common ownership or confirm identity.
- Cure Ventures Fund II, L.P. · CIK 2094337
Form D filings (2)
-
0002067583-26-000002D · Oct 20, 2026 · PharmaceuticalsOffering: $5,500,000Sold: $5,500,000
Compared with 0002067583-25-000002:
- Reported offering amount: $8,000,000 → $5,500,000
- Reported amount sold: $4,250,000 → $5,500,000
- Reported investor count: Unavailable → 8
-
0002067583-25-000002D · May 15, 2025 · PharmaceuticalsOffering: $8,000,000Sold: $4,250,000